By HeartFlowLearning Objectives
- Understand what HeartFlow does and the invasive test it can help avoid
- Learn why FDA clearance and reimbursement make it a mature clinical AI
- Identify where HeartFlow fits in the diagnosis of heart disease
What Is HeartFlow?
HeartFlow applies AI to one of the most consequential questions in cardiology: is a narrowing in a coronary artery actually restricting blood flow enough to matter? Traditionally, answering that with confidence could require an invasive procedure — threading a catheter into the heart to measure pressure. HeartFlow''s FFR-CT technology models that blood flow from a standard, non-invasive coronary CT scan instead, building a personalized 3D model of the patient's arteries and simulating the flow through them.
The result helps cardiologists decide whether a blockage is significant and how to treat it — often without the cost and risk of an invasive test. Newer HeartFlow products go further, characterizing and quantifying arterial plaque to assess heart-disease risk. Because the technology is FDA-cleared and reimbursed, HeartFlow is one of the most established and clinically-validated AI tools in all of medical imaging — a long way from experimental.
💡Key Concept
Why this is a model for medical AI: HeartFlow shows what mature clinical AI looks like — FDA-cleared, reimbursed, validated in studies, and aimed at replacing an invasive, expensive test with a non-invasive analysis. The AI informs the cardiologist's decision; it does not make the diagnosis alone.
✅Tip
Visit HeartFlow: heartflow.com — a clinical service used by hospitals and cardiology practices; analyses are ordered by clinicians, not patients.
Core Capabilities
FFR-CT Blood-Flow Analysis
From a standard coronary CT angiogram, HeartFlow builds a 3D model of the patient's coronary arteries and computes how much each narrowing actually restricts blood flow — the kind of functional information that previously required an invasive catheter measurement.
Plaque Analysis
HeartFlow''s plaque products characterize and quantify the buildup in the arteries, giving cardiologists more information about heart-disease risk and how aggressively to treat it.
Decision Support for Treatment
By distinguishing blockages that meaningfully restrict flow from those that do not, HeartFlow helps care teams decide who needs an intervention and who can be managed with medication — targeting care more precisely.
A Clinical Service
HeartFlow is delivered as a clinical service: a hospital sends the CT data, and HeartFlow returns the analysis for the cardiologist to interpret as part of the patient's care.
Strengths
- Non-invasive — provides functional blood-flow information without a catheter procedure
- FDA-cleared and reimbursed — a mature, validated clinical tool, not an experiment
- Clinically established — long track record and study evidence behind it
- Targets better decisions — helps avoid unnecessary invasive tests and target treatment
Limitations & Considerations
- Requires a quality CT — the analysis depends on a good coronary CT angiogram as input
- Decision support, not autonomy — it informs the cardiologist, who makes the diagnosis and treatment plan
- Cardiac-specific — HeartFlow addresses coronary artery disease, not imaging broadly
- Access and cost — availability depends on the hospital offering the service and on local reimbursement
Best Use Cases
| Task | Why HeartFlow |
|---|---|
| Assessing whether a coronary narrowing limits blood flow | Non-invasive FFR-CT from a standard CT scan |
| Avoiding an unnecessary invasive heart procedure | Functional information without a catheter |
| Assessing heart-disease risk from plaque | Plaque characterization and quantification |
| Targeting who needs intervention versus medication | Flow analysis distinguishes significant blockages |
Getting Started
- HeartFlow is ordered by a cardiologist as part of a patient's evaluation, not by patients directly
- The patient has a standard coronary CT angiogram at a participating facility
- The scan data is sent to HeartFlow, which returns the FFR-CT and plaque analysis
- The cardiologist interprets the results alongside the full clinical picture to plan care
Key Takeaways
- HeartFlow uses AI to model coronary blood flow from a non-invasive CT scan, often avoiding an invasive test
- Its FFR-CT and plaque analyses help cardiologists decide whether a blockage matters and how to treat it
- It is FDA-cleared and reimbursed — one of the most mature and validated AI tools in medical imaging
- The AI supports the cardiologist's decision; the diagnosis and treatment plan remain the clinician's
